NinePointTwo Capital’s Bristol-Myers Squibb BMY Stock Holding History

NinePointTwo Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,541	Closed	-$205K	–	256
2023 Q3	$205K	Hold	3,541	–	–	0.08%	204
2023 Q2	$226K	Hold	3,541	–	–	0.09%	175
2023 Q1	$245K	Buy	+3,541	New	+$250K	0.09%	146

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

NinePointTwo Capital's BMY Position: Q4 2023 in Review

NinePointTwo Capital sold out of Bristol-Myers Squibb (BMY) in Q4 2023, closing a stake of 3,541 shares — an estimated $205K sold.

NinePointTwo Capital first reported a position in BMY in Q1 2023 and held it in 3 quarters. The position peaked at $245K in Q1 2023. 2,363 funds tracked by Wall St. Rank hold BMY as of Q4 2023.

NinePointTwo Capital reported no remaining Bristol-Myers Squibb position as of Q4 2023 after selling out during the quarter.
NinePointTwo Capital sold 3,541 Bristol-Myers Squibb shares in Q4 2023, an estimated $205K.
NinePointTwo Capital first reported a position in Bristol-Myers Squibb in Q1 2023 and held it in 3 quarters.
NinePointTwo Capital's Bristol-Myers Squibb position peaked at $245K in Q1 2023.
2,363 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.